Cerebrospinal fluid markers in Creutzfeldt-Jakob disease

被引：29

作者：

Skinningsrud A. ^{[1
]}

Stenset V. ^{[2
,3
]}

Gundersen A.S. ^{[2
,3
]}

Fladby T. ^{[2
,3
]}

机构：

[1] Multidisciplinary Medical Laboratory, Akershus University Hospital

[2] Department of Neurology, Akershus University Hospital

[3] University of Oslo, Oslo

来源：

Cerebrospinal Fluid Research | / 5卷 / 1期

关键词：

Prion Protein; Bovine Spongiform Encephalopathy; Scrapie; Magnetic Resonance Finding; Classical Scrapie;

D O I：

10.1186/1743-8454-5-14

中图分类号：

学科分类号：

摘要：

Background: The objective was to assess the utility of total tau protein(tTau), the ratio of (tTau)/181 phosphorylated tau protein (P-Tau and 14-3-3 protein, as diagnostic markers in cerebrospinal fluid (CSF) for Creutzfeldt-Jakob disease (CJD). Methods: CSF samples received from Norwegian hospitals between August 2005 and August 2007 were retrospectively selected from consecutive patients with tTau values > 1200 ng/L (n = 38). The samples from patients clinically diagnosed with CJD (n = 12) were compared to those from patients with other degenerative neurological diseases: Alzheimer's/ vascular dementia (AD/VaD, n = 21), other neurological diseases (OND, n = 5). Total Tau, P-Tau, and β-Amyloid (Aβ42) were measured with commercial kits. Additionally, 14-3-3 protein was measured semi-quantitatively by immunoblot. Results: The minimum cut-off limits for diagnosis of CJD were chosen from the test results. For tTau the lower limit was fixed at 3000 ng/L, for the tTau/P-Tau ratio it was 60, and for 14-3-3 protein it was 0.75 arbitrary units. For tTau and tTau/P-Tau ratio, all but three CJD patients had levels above the minimum, whereas almost all of the other patients were below. For the 14-3-3 protein, two CJD patients were below the minimum and five were above. Only one of the other patients was higher than the limit. The sensitivities, specificities and diagnostic efficiencies were: tTau 75%, 92%, and 87%; tTau/P-Tau 75%, 96%, and 89%; and 14-3-3 protein 80%, 96%, and 91%. Conclusion: The results suggest that 14-3-3 protein may be the better marker for CJD, tTau/P-Tau ratio and tTau are also efficient markers, but showed slightly inferior diagnostic properties in this study, with tTau/P-Tau marginally better than tTau. © 2008 Skinningsrud et al; licensee BioMed Central Ltd.

引用

共 15 条

[1]

Ladogana A., Puopolo M., Croes E.A., Budka H., Jarius C., Collins S., Klug G.M., Sutcliffe T., Giulivi A., Alperovitch A., Delasnerie-Laupretre N., Brandel J.P., Poser S., Kretzschmar H., Rietveld I., Mitrova E., Cuesta Jde P., Martinez-Martin P., Glatzel M., Aguzzi A., Knight R., Ward H., Pocchiari M., van Duijn C.M., Will R.G., Zerr I., Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada, Neurology, 64, pp. 1586-1591, (2005)

[2]

Collinge J., Molecular neurology of prion disease, J Neurol Neurosurg Psychiat, 76, pp. 906-919, (2005)

[3]

Benestad S.L., Sarradin P., Thu B., Schonheit J., Tranulis M.A., Bratberg B., Cases of scrapie with unusual features in Norway and designation of a new type, Nor98, Vet Rec, 153, pp. 202-208, (2003)

[4]

Otto M., Wiltfang J., Tumani H., Zerr I., Lantsch M., Kornhuber J., Weber T., Kretzschmar H.A., Poser S., Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, Neurosci Lett, 225, pp. 210-212, (1997)

[5]

Strozyk D., Blennow K., White L.R., Launer L.J., CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study, Neurology, 60, pp. 652-656, (2003)

[6]

Rank K.B., Pauley A.M., Bhattacharya K., Wang Z., Evans D.B., Fleck T.J., Johnston J.A., Sharma S.K., Direct interaction of soluble human recombinant tau protein with Abeta 1-42 results in tau aggregation and hyperphosphorylation by tau protein kinase II, FEBS Lett, 514, pp. 263-268, (2002)

[7]

Riemenschneider M., Wagenpfeil S., Vanderstichele H., Otto M., Wiltfang J., Kretzschmar H., Vanmechelen E., Forstl H., Kurz A., Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias, Mol Psychiatry, 8, pp. 343-347, (2003)

[8]

Satoh K., Shirabe S., Eguchi H., Tsujino A., Eguchi K., Satoh A., Tsujihata M., Niwa M., Katamine S., Kurihara S., Matsuo H., 14-3-3 protein, total tau and phosphorylated tau in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease and neurodegenerative disease in Japan, Cell Mol Neurobiol, 26, 1, pp. 45-52, (2006)

[9]

Van Everbroeck B., Green A.J., Vanmechelen E., Vanderstichele H., Pals P., Sanchez-Valle R., Corrales N.C., Martin J.J., Cras P., Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease, J Neurol Neurosurg Psychiat, 73, pp. 79-81, (2002)

[10]

Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: Report from a WHO consultation, Emerging and Other Communicable Diseases, Surveillance and Control, pp. 1-26, (1998)

← 1 2 →